{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:48:14Z","timestamp":1793674094679,"version":"4.5.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Benzodiazepines (BZDs) are recommended as the initial therapy of choice in status epilepticus (SE). The age-old second-line treatment for BZD refractory convulsive SE is intravenous phenytoin (PHT) based predominantly on nonrandomized clinical trial data. We did this study to compare the efficacy and safety of intravenous levetiracetam (LEV) and PHT as second-line antiseizure medication (ASM) for children with SE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology:<\/jats:title>\n                    <jats:p>A prospective, randomized controlled, open-label study was conducted in children 3 months to 15 years of age with SE in Pediatric Emergency. A total of 41 children were randomly allocated to either group 1 (Levetiracetam) or group 2 (Phenytoin) on the basis of computer-generated randomization. Children who were already on antiseizure medications, either LEV or PHT, or receiving these drugs outside for SE were excluded. Data analysis was done by SPSS V25<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The most common age group presenting with SE was 12 months to 5 years. Clinical cessation of seizure 5 minutes after the completion of drugs was 85% (17\/20) in Levetiracetam group and 90.5% (19\/21) in Phenytoin group. Recurrence of seizure within 24 hours was noted in 35% (7\/20) in Levetiracetam group and 38.1% (8\/21) in Phenytoin group. There was no statistically significant difference noted in both the groups in terms of seizure cessation, adverse events, and recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The efficacy and safety of LEV were found to be comparable to those of PHT in controlling seizure as second-line ASM in SE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_1747_23","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T02:09:08Z","timestamp":1721959748000},"page":"3368-3373","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Intravenous levetiracetam versus intravenous phenytoin as second Line treatment in pediatric convulsive status epilepticus- open label randomized controlled trial"],"prefix":"10.4103","volume":"13","author":[{"given":"Mamum","family":"Kartek","sequence":"first","affiliation":[{"name":"Department of Pediatrics, TRIHMS, Naharlagun, Arunachal Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abinaya","family":"Kannan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, AIIMS, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Trauma and Emergency, AIIMS, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manas R.","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, AIIMS, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus--Report of the ILAE task force on classification of status epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12028-013-9935-x","article-title":"The epidemiology of status epilepticus in the United States","volume":"20","author":"Dham","year":"2014","journal-title":"Neurocrit Care"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","article-title":"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): A double-blind, responsive-adaptive, randomised controlled trial","volume":"395","author":"Chamberlain","year":"2020","journal-title":"Lancet"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","article-title":"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): A multicentre, open-label, randomised trial","volume":"393","author":"Lyttle","year":"2019","journal-title":"Lancet"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13312-020-1755-4","article-title":"Comparison of phenytoin, valproate and levetiracetam in pediatric convulsive status epilepticus: A randomized double-blind controlled clinical trial","volume":"57","author":"Vignesh","year":"2020","journal-title":"Indian Pediatr"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12887-017-0887-8","article-title":"A multicentre randomised controlled trial of levetiracetam versus phenytoin for convulsive status epilepticus in children (protocol): Convulsive status epilepticus paediatric trial (ConSEPT) - A PREDICT study","volume":"17","author":"Dalziel","year":"2017","journal-title":"BMC Pediatr"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"878","DOI":"10.18203\/2349-3291.ijcp20171690","article-title":"A study of the etiology and short term outcome of status epilepticus in children","volume":"4","author":"Selvan","year":"2017","journal-title":"Int J Contemp Pediatr"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF02760691","article-title":"Status epilepticus in Indian children in a tertiary care center","volume":"72","author":"Gulati","year":"2005","journal-title":"Indian J Pediatr"},{"key":"R9-20240828","first-page":"PC14","article-title":"Clinical profile of status epilepticus (SE) in children in a tertiary care hospital in Bihar","volume":"8","author":"Kumar","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1111\/j.1528-1167.2007.01214.x","article-title":"Convulsive status epilepticus: Clinical profile in a developing country","volume":"48","author":"Murthy","year":"2007","journal-title":"Epilepsia"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.18535\/jmscr\/v5i1.109","article-title":"Clinical profile, aetiology, and short term outcome of convulsive status epilepticus in children in Eastern India","volume":"5","author":"Das","year":"2017","journal-title":"J Med Sci Clin Res"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.4103\/jfmpc.jfmpc_750_19","article-title":"Levetiracetam versus phenytoin in children with status epilepticus","volume":"8","author":"Wani","year":"2019","journal-title":"J Fam Med Prim Care"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"237","DOI":"10.17511\/ijpr.2018.i04.13","article-title":"Randomized controlled trial of levetiracetam versus fosphenytoin for convulsive status epilepticus in children","volume":"5","author":"Senthilkumar","year":"2018","journal-title":"Pediatr Rev Int J Pediatr Res"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4103\/JPN.JPN_126_17","article-title":"IV Levetiracetam versus IV phenytoin in childhood seizures: A randomized controlled trial","volume":"13","author":"Singh","year":"2018","journal-title":"J Pediatr Neurosci"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.seizure.2017.05.001","article-title":"Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study","volume":"49","author":"Gujjar","year":"2017","journal-title":"Seizure"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1747_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:58:14Z","timestamp":1787839094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1747_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1747_23","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"2023-10-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}